Kết quả bước đầu của liệu pháp nhiệt hơi nước rezum điều trị tăng sinh lành tính tuyến tiền liệt: Báo cáo ba trường hợp tại Bệnh viện Trung ương Quân đội 108

Abstract

Objective: To evaluate the preliminary outcomes of Rezūm water vapor therapy in the treatment of benign prostatic hyperplasia (BPH) at the 108 Military Central Hospital. Subject and method: We conducted a descriptive case series of three patients diagnosed with BPH who underwent Rezūm water vapor therapy at the Lower Urology Unit, 108 Military Central Hospital, from July to August 2025. Result: The three patients were aged 63–82 years. At baseline, the median International Prostate Symptom Score (IPSS) was 23, the median quality-of-life (QoL) score was 5, the median maximum urinary flow rate (Qmax) was 8.5mL/s, the median prostate volume was 58mL, and total prostate-specific antigen (PSA) ranged from 0.51 to 13.13ng/mL. At one-month post-procedure, the median IPSS decreased by 60.8%; the median QoL score decreased by 60%; the median Qmax increased by 4.9mL/s; the median prostate volume decreased by 1.7%; and the median post-void residual volume decreased by 47mL. The median procedural time was 10 minutes; the median number of injections was 8; the median urethral catheterization time was 7.0 days; and 100% of patients achieved spontaneous voiding within two weeks of the intervention. Total PSA declined in parallel with the reduction in prostate volume. No new complaints of sexual dysfunction were reported during the first month; however, longer-term follow-up is warranted. Conclusions: Rezūm water vapor therapy is a simple, safe, and time-efficient treatment that provides early improvement in lower urinary tract symptoms, with no early sexual adverse effects observed after the intervention.